ANGIODYNAMICS INC — Director's Dealing 2020

Sep 14, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ANGIODYNAMICS INC (ANGO)
CIK: 0001275187
Period of Report: 2020-09-03

Reporting Person: Centea Scott (SVP/GM, VIT)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	45853	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Non-Qualified Stock Option (right to buy)	$9.92	2030-07-14	Common Stock (17640)		Direct
Performance Right	$		Common Stock (11782)		Direct
Non-Qualified Stock Option (right to buy)	$15.30	2029-10-31	Common Stock (50000)		Direct
Non-Qualified Stock Option (right to buy)	$16.77	2024-10-24	Common Stock (12000)		Direct

Footnotes

F1: This number includes (i) 5,891 shares of common stock of AngioDynamics, Inc. ("Common Stock") underlying restricted stock units which vest in four equal annual installments beginning on July 14, 2021, such that 25% of the restricted stock units will vest on each of July 14, 2021, 2022, 2023 and 2024, (ii) 10,000 shares of Common Stock underlying restricted stock units which vest in four equal annual installments beginning on October 31, 2020, such that 25% of the restricted stock units will vest on each of October 31, 2020, 2021, 2022 and 2023, (iii) 2,995 shares of Common Stock underlying restricted stock units which vest in three equal annual installments on each of July 17, 2021, 2022 and 2023, (iv) 2,031 shares of Common Stock underlying restricted stock units which vest in two equal annual installments on each of July 18, 2021 and 2022, and (v) 1,101 shares of Common Stock underlying restricted stock units which vest on July 26, 2021.

F2: These stock options vest in four equal annual installments beginning on July 14, 2021, such that 25% of the options will vest on each of July 14, 2021, 2022, 2023 and 2024.

F3: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned may be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F4: These stock options vest in four equal annual installments beginning on October 31, 2020, such that 25% of the options will vest on each of October 31, 2020, 2021, 2022 and 2023.

F5: These stock options have fully vested and are exercisable.